We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MicroRNAs Differentiate Between Primary and Metastatic Brain Tumors

By Labmedica staff writers
Posted on 21 Jul 2008
MicroRNAs were used to differentiate between primary and metastatic tumors of the brain.

MicroRNAs (miRNAs) are naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. MicroRNAs have been shown to have different expression profiles in various pathological conditions. These differences provide a novel diagnostic strategy for many diseases.

A study conducted by Rosetta Genomics' (Rehovot, Israel) scientist Nitzan Rosenfeld and colleagues from five different Israeli medical centers demonstrated microRNAs' potential to act as effective biomarkers that could be applied in a diagnostic test to identify primary tumors in patients with brain cancer. The study results, published in the June 8, 2008 online edition of Brain Pathology, describe the development and validation of microRNA expression profiles for characterization of brain malignancies.

MicroRNA expression was measured in RNA extracted from hundreds of formalin-fixed, paraffin-embedded (FFPE) samples of brain primary tumors and other tissues, as well as 60 samples of metastatic brain tumors. Two microRNAs, miR-92b and miR-9/9*, were found to be significantly over-expressed in brain primary tumors, and may represent potential biomarkers for the identification of these tumors. The study demonstrated, based on a blinded test set, that the overall sensitivity and specificity of this classifier are approximately 90%.

The study authors wrote: "By considering the expression of only these two microRNAs, it is possible to distinguish between primary and metastatic brain tumors with very high accuracy. These microRNAs thus represent excellent biomarkers for brain primary tumors. Previous reports have found that hsa-miR-92b and hsa-miR-9/hsa-miR-9* are expressed more strongly in developing neurons and brain than in adult brain. Thus, their specific over-expression in brain primary tumors supports a functional role for these microRNAs or a link between neuronal stem cells and brain tumorigenesis.”


Related Links:
Rosetta Genomics

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Lab Autoclave
T-Lab Eco
New
Vedolizumab ELISA
RIDASCREEN VDZ Monitoring

Latest Molecular Diagnostics News

Early Blood Test Predicts Survival in Patients with Metastatic Prostate Cancer

POC Sepsis Test Delivers Fast, Accurate and User-Friendly Results in Critical Care Settings

Experimental Blood Test Improves Detection of Early-Stage Pancreatic Cancer